Climb Bio, Inc.
CLYM
$2.33
-$0.15-6.05%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -27.92% | 14.92% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -53.61% | 110.96% | |||
| Operating Income | 53.61% | -110.96% | |||
| Income Before Tax | 58.30% | -146.92% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 58.30% | -146.92% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 58.30% | -146.92% | |||
| EBIT | 53.61% | -110.96% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 58.38% | -136.92% | |||
| Normalized Basic EPS | 59.69% | -124.27% | |||
| EPS Diluted | 58.38% | -136.92% | |||
| Normalized Diluted EPS | 59.69% | -124.27% | |||
| Average Basic Shares Outstanding | 0.18% | 4.21% | |||
| Average Diluted Shares Outstanding | 0.18% | 4.21% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||